The last Friday Sarthak Metals hit a 52 week high of Rs 179.25. The scrip has gained 38% in the last one month. This validates what Wisdomsmith has been saying about Sarthak, that it is a high quality stock, due for a re-rating. Even at the 52 week high, Sarthak…
Read More After the second quarter FY23 results for Sarthak Metals, we wrote to investors reiterating the market was undervaluing the company. Now comes the news that central government has rolled back export duty for some steel intermediates. A 50% tax on exports of iron-ore lumps will be reversed just a few…
Read More
CL Educate Limited informed the exchanges on Saturday that it is selling one of its last two surplus real estate assets. Career Launcher Infrastructure Private Limited (wholly owned Subsidiary of CL Educate Limited) has entered into an ‘Agreement to Sell’ dated September 23, 2022 for its Land and Building admeasuring…
Read More
Indrayani Biotech (BSE: 526445) is a growth stock that is likely to show strong double digit growth over the next few years. In its Annual Report released the last week, the company has projected a consolidated revenue of Rs 150 crore for FY23. In comparison, the revenue for FY22 was Rs…
Read More Our new Investor Relations client Sarthak Metals offers great value to investors at the current price. Firstly, its business: Sarthak Metals is a supplier of couple of important ingredients in the manufacture of steel. While the name may suggest that Sarthak is a manufacturer of metals, it is a supplier…
Read More FY22 saw CL Educate once again moving ahead purposefully. Several positives emerged: Reported EBITDA had a healthy look, growth returned, surplus real estate was partly disposed, debt reduced and net cash increased, merger of subsidiaries got consummated. The management is now firmly focused on pursuing growth objectives in both EdTech…
Read More
2022 is witnessing a sharp drop in global biotech investments by venture capital funds. Data compiled by Wisdomsmith shows venture capital funds invested $15.8B in biotech and healthcare sector over Jan-Apr’22, as compared to $27B over the same period in 2021. That’s a drop of 41%. While the drop…
Read More
The first half of FY22 has seen some significant steps taken by the Chemcrux management, that signify a more aggressive intent towards the future growth of the company. Financial performance of FY22H1 has been good as well, with net profit increasing 16% over FY21H1, which was impacted by Covid. The…
Read More We have written earlier that Edtech and Martech player CL Educate is a stock in a positive upcycle. FY22 has already seen a chain of positive developments. CL’s newsletter for its Test Prep business for Nov’21 shows the rapid pace of developments at the company. Some key snippets: CL is…
Read More
After the FY21 year-end result of CL Educate, we wrote in June’21: In fact, when it looks back at FY21 many years later, it may find that it was a key turning point in its corporate journey. Then after Q1 FY22 results, we wrote in Aug’21: After 2 years –…
Read More